Rezolute, Inc. (RZLT)

Market Cap	229.67M -2.0%
Revenue (ttm)	n/a
Net Income	-84.23M
EPS	-0.91
Shares Out	95.70M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,042,818
Open	2.510
Previous Close	2.490
Day's Range	2.380 - 2.530
52-Week Range	1.070 - 11.457
Beta	0.64
Analysts	Strong Buy
Price Target	9.17 (+282.08%)
Earnings Date	May 12, 2026

About RZLT

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 75
• Stock Exchange: NASDAQ
• Ticker Symbol: RZLT
• Website: https://www.rezolutebio.com

Analyst Summary

According to 6 analysts, the average rating for RZLT stock is "Strong Buy." The 12-month stock price target is $9.17, which is an increase of 282.08% from the latest price.

Price Target

$9.17

(282.08% upside)

Analyst Consensus: Strong Buy